NCT04415853View on ClinicalTrials.gov

Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

416

Participants

Timeline

Start Date

January 21, 2021

Primary Completion Date

August 31, 2026

Study Completion Date

December 30, 2026

Conditions
Esophageal Cancer
Interventions
DRUG

Lerotinib

Specification: 50 mg/capsule and 150 mg/capsule

DRUG

Irinotecan/Tegafur

Irinotecan:Specification: 2mL: 40mg;5mL:0.1g Tegafur:20mg/capsule

Trial Locations (1)

100036

RECRUITING

Chinese PLA General Hospital, Beijing

All Listed Sponsors
lead

Sunshine Lake Pharma Co., Ltd.

INDUSTRY